The potential of liquid biopsies

Current Opinion in Oncology

Volumn 28, Issue 2, 2016, Pages 130-134

  Buder, Anna ^a   Tomuta, Christian ^a   Filipits, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

circulating cell free tumor DNA; circulating tumor cells; exosomes; resistance monitoring; therapy monitoring

Indexed keywords

AFATINIB; BIOLOGICAL MARKER; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEFITINIB; MICRORNA; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; DNA; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

CANCER GROWTH; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; EXOSOME; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LUNG BIOPSY; METASTASIS; MINIMAL RESIDUAL DISEASE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THERAPY RESISTANCE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; PATHOLOGY; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; EXOSOMES; HUMANS; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 84957698834     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000267     Document Type: Review

References (25)

1. Heitzer E. Clinical utility of circulating tumor DNA in human cancers. Memo 2015; DOI 10.1007/s12254-015-0217-5.
2. Hamilton G. Clinical relevance of circulating tumor cells in cancer patients. Memo 2015; DOI 10.1007/s12254-015-0237-1.
3. Senfter D, Mader RM. Exosomes as novel biomarkers in anticancer therapy. Memo 2015; DOI 10.1007/s12254-015-0245-1.
4. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61:1659-1665.
5. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37:646-650.
6. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6:224ra224.
7. Tseng JS, Yang TY, Tsai CR, et al. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2015; 10:603-610.
8. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015; 90:509-515.
9. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20:1698-1705.
10. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792.
11. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31:3987-3996.
12. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant nonsmall-cell lung cancer. N Engl J Med 2015; 372:1689-1699.
13. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated nonsmall-cell lung cancer. N Engl J Med 2015; 372:1700-1709.
14. Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in nonsmall cell lung cancer patients. Clin Cancer Res 2009; 15:2076-2084.
15. Tissot C, Toffart AC, Villar S, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J 2015; 46:1773-1780.
16. Ilie M, Hofman V, Long-Mira E, et al. 'Sentinel' circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014; 9:e111597.
17. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359:366-377.
18. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012; 18:2391-2401.
19. Nelson NJ. Circulating tumor cells: will they be clinically useful? J Natl Cancer Inst 2010; 102:146-148.
20. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339:580-584.
21. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene 2015. [Epub ahead of print]
22. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: A novel biomarker in cancer detection. Cell Res 2014; 24:766-769.
23. Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015; 4:27066.
24. Camussi G, Deregibus MC, Bruno S, et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010; 78:838-848.
25. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10:42-46.